Next Article in Journal
Orthopoxvirus Zoonoses—Do We Still Remember and Are Ready to Fight?
Next Article in Special Issue
The Global Expansion of LTBI Screening and Treatment Programs: Exploring Gaps in the Supporting Economic Evidence
Previous Article in Journal
Major Depressive Disorder and Pulmonary Tuberculosis Comorbidity Exacerbates Proinflammatory Immune Response—A Preliminary Study
Previous Article in Special Issue
Landscape of TB Infection and Prevention among People Living with HIV
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges

1
University of Montpellier, TransVIHMI, Institut de Recherche pour le Développement (IRD), Institut National de la Santé et de la Recherche Médicale (INSERM), 34090 Montpellier, France
2
Institut de Recherches Cliniques du Bénin (IRCB), Abomey-Calavi, Benin
3
Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
*
Author to whom correspondence should be addressed.
Pathogens 2023, 12(3), 362; https://doi.org/10.3390/pathogens12030362
Submission received: 6 December 2022 / Revised: 13 February 2023 / Accepted: 16 February 2023 / Published: 21 February 2023

Abstract

Tuberculosis infection (TBI) is defined as a state of infection in which individuals host live Mycobacterium tuberculosis with or without clinical signs of active TB. It is now understood as a dynamic process covering a spectrum of responses to infection resulting from the interaction between the TB bacilli and the host immune system. The global burden of TBI is about one-quarter of the world’s population, representing a reservoir of approximately 2 billion people. On average, 5–10% of people who are infected will develop TB disease over the course of their lives, but this risk is enhanced in a series of conditions, such as co-infection with HIV. The End-TB strategy promotes the programmatic management of TBI as a crucial endeavor to achieving global targets to end the TB epidemic. The current development of new diagnostic tests capable of discriminating between simple TBI and active TB, combined with novel short-course preventive treatments, will help achieve this goal. In this paper, we present the current situation and recent developments of management of TBI and the operational challenges.
Keywords: TB infection; TB preventive therapy; TB high- and low-burden countries; cost-effectiveness; WHO recommendations TB infection; TB preventive therapy; TB high- and low-burden countries; cost-effectiveness; WHO recommendations

Share and Cite

MDPI and ACS Style

Agbota, G.; Bonnet, M.; Lienhardt, C. Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges. Pathogens 2023, 12, 362. https://doi.org/10.3390/pathogens12030362

AMA Style

Agbota G, Bonnet M, Lienhardt C. Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges. Pathogens. 2023; 12(3):362. https://doi.org/10.3390/pathogens12030362

Chicago/Turabian Style

Agbota, Gino, Maryline Bonnet, and Christian Lienhardt. 2023. "Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges" Pathogens 12, no. 3: 362. https://doi.org/10.3390/pathogens12030362

APA Style

Agbota, G., Bonnet, M., & Lienhardt, C. (2023). Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges. Pathogens, 12(3), 362. https://doi.org/10.3390/pathogens12030362

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop